Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: Combined analysis of two phase III trials (NEJ 002 and WJTOG 3405)

Japanese Journal of Clinical Oncology

Volumn 43, Issue 6, 2013, Pages 664-668

  Akamatsu, Hiroaki ^a   Inoue, Akira ^b   Mitsudomi, Tetsuya ^c   Kobayashi, Kunihiko ^d   Nakagawa, Kazuhiko ^c   Mori, Keita ^a   Nukiwa, Toshihiro ^b,e   Nakanishi, Yoichi ^f   Yamamoto, Nobuyuki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^e South Miyagi Medical Center   (Japan)

^f KYUSHU UNIVERSITY   (Japan)

Author keywords

Epidermal growth factor receptor mutation; Epidermal growth factor receptor tyrosine kinase inhibitor; Gefitinib; Interstitial lung disease; Japanese

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEFITINIB; PACLITAXEL; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; DRUG SAFETY; EXON; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; JAPANESE; LUNG LAVAGE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); SMOKING; STEROID THERAPY;

EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION; EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR; GEFITINIB; INTERSTITIAL LUNG DISEASE; JAPANESE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PLATINUM; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING;

EID: 84878663933     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt049     Document Type: Article

References (16)

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350: 2129-39.
2. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
3. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
4. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
5. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42.
6. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
7. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-9.
8. Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-56.
9. Kudoh S, Kato H, Nishiwaki Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 2008;177:1348-57.
10. Nakagawa K, Kudoh S, Ohe Y, et al. Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR). J Thorac Oncol 2012;7:1296-303.
11. Cohen MH, Johnson JR, Chattopadhyay S, et al. Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC). Oncologist 2010;15:1344-51.
12. Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29:2121-7.
13. Yatabe Y, Hida T, Horio Y, Kosaka T, Takahashi T, Mitsudomi T. A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn 2006;8:335-41.
14. Nagai Y, Miyazawa H, Huqun, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005;65:7276-82.
15. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183: 788-824.
16. Harada C, Kawaguchi T, Ogata-Suetsugu S, et al. EGFR tyrosine kinase inhibition worsens acute lung Injury in mice with repairing airway epithelium. Am J Respir Crit Care Med 2011;183:743-51.